Clinical Trials Browser

Phase 4 × Interventional × fosaprepitant × Clear all

NCT05841849 2023-05-03

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Phase 4 Not yet recruiting

Breast Neoplasms, Vomiting

NCT01432015 2017-03-28

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Phase 4 Completed

20 enrolled 5 charts

Ovarian Neoplasms, Uterine Neoplasms, Vomiting